These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2550593)

  • 1. Variability in the proliferative potential of human gliomas.
    Hoshino T; Nagashima T; Cho KG; Davis RL; Donegan J; Slusarz M; Wilson CB
    J Neurooncol; 1989 Jul; 7(2):137-43. PubMed ID: 2550593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
    Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
    Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas.
    Hoshino T; Prados M; Wilson CB; Cho KG; Lee KS; Davis RL
    J Neurosurg; 1989 Sep; 71(3):335-41. PubMed ID: 2549222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
    Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
    Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
    Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
    J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
    Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
    Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric central nervous system tumors: a cell kinetic study with bromodeoxyuridine.
    Murovic JA; Nagashima T; Hoshino T; Edwards MS; Davis RL
    Neurosurgery; 1986 Dec; 19(6):900-4. PubMed ID: 3027608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A correlative study of gliomas using in vivo bromodeoxyuridine labeling index and computer-aided malignancy grading.
    Sharma S; Karak AK; Singh R; Mehta VS; Sarkar C; Schmitt HP
    Pathol Oncol Res; 1999; 5(2):134-41. PubMed ID: 10393366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of the proliferative potential of low-grade astrocytomas.
    Hoshino T; Rodriguez LA; Cho KG; Lee KS; Wilson CB; Edwards MS; Levin VA; Davis RL
    J Neurosurg; 1988 Dec; 69(6):839-42. PubMed ID: 3193189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of CT contrast enhancement and BUDR labeling indices in moderately and highly anaplastic astrocytomas of the cerebral hemispheres.
    McDermott MW; Krouwer HG; Asai A; Ito S; Hoshino T; Prados MD
    Can J Neurol Sci; 1992 Feb; 19(1):34-9. PubMed ID: 1562905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of histopathological features and proliferative potential of gliomas.
    Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
    J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.
    Ito S; Hoshino T; Shibuya M; Prados MD; Edwards MS; Davis RL
    Neurosurgery; 1992 Sep; 31(3):413-8; discussion 419. PubMed ID: 1407423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of 201Tl SPECT in patients with glioma: a comparative study with histological diagnosis, clinical feature and proliferative activity].
    Oriuchi N; Tamura M; Shibazaki T; Inoue T; Watanabe N; Tateno M; Tomiyoshi K; Hirano T; Igarashi H; Endo K
    Kaku Igaku; 1991 Nov; 28(11):1263-71. PubMed ID: 1770641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults.
    Fujimaki T; Matsutani M; Nakamura O; Asai A; Funada N; Koike M; Segawa H; Aritake K; Fukushima T; Houjo S
    Cancer; 1991 Mar; 67(6):1629-34. PubMed ID: 2001552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme.
    Ritter AM; Sawaya R; Hess KR; Levin VA; Bruner JM
    Neurosurgery; 1994 Aug; 35(2):192-8; discussion 198. PubMed ID: 7969825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
    Nagashima T; Hoshino T
    No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell kinetics of glial tumors.
    Hoshino T
    Rev Neurol (Paris); 1992; 148(6-7):396-401. PubMed ID: 1448658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative potential and outcome in pediatric astrocytic tumors.
    Prados MD; Krouwer HG; Edwards MS; Cogen PH; Davis RL; Hoshino T
    J Neurooncol; 1992 Jul; 13(3):277-82. PubMed ID: 1325544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative potential and prognostic evaluation of low-grade astrocytomas.
    Ito S; Chandler KL; Prados MD; Lamborn K; Wynne J; Malec MK; Wilson CB; Davis RL; Hoshino T
    J Neurooncol; 1994; 19(1):1-9. PubMed ID: 7815099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A cell kinetic study of human central nervous system tumors with 5-bromodeoxyuridine (BrdU)].
    Nagashima T; Hoshino T
    No To Shinkei; 1985 Dec; 37(12):1195-201. PubMed ID: 3912000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.